Analysis: FDA Warning Letters in 2011 Mostly Focused on Batch Failures

Posted 25 April 2012 | By Alexander Gaffney, RAC 

An analysis of US Food and Drug Administration (FDA) warning letters issued in 2011 shows the majority of all facilities receiving a warning letter were deficient in areas relating to batch failure investigation, reports In-Pharma Technologist.

"In the manufacturing-related warning letters analyzed by in-Pharma Technologist, FDA made 211 numbered observations," of which 10% were related to the company not investigating batch failures.

Despite only 10% of all observations being about batch failures, almost half of all facilities receiving a warning letter were cited for "failure to thoroughly investigate batch failure," notes in-Pharma Technologist.

In-Pharma Technologist's analysisalso noted that an additional third of all companies receiving warning letters were warned after FDA found they did not have written procedures to ensure quality.

Read more:

In-Pharma Technologist - Half of FY11 FDA GMP warning letters tied to batch failures

Regulatory Focus newsletters

All the biggest regulatory news and happenings.